Gilead Sciences (GILD) Short term Debt (2016 - 2025)
Historic Short term Debt for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $2.8 billion.
- Gilead Sciences' Short term Debt rose 5485.65% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 5485.65%. This contributed to the annual value of $1.8 billion for FY2024, which is 94.55% up from last year.
- Per Gilead Sciences' latest filing, its Short term Debt stood at $2.8 billion for Q3 2025, which was up 5485.65% from $2.8 billion recorded in Q2 2025.
- In the past 5 years, Gilead Sciences' Short term Debt ranged from a high of $4.0 billion in Q2 2023 and a low of $1.0 billion during Q2 2022
- In the last 5 years, Gilead Sciences' Short term Debt had a median value of $2.3 billion in 2021 and averaged $2.2 billion.
- As far as peak fluctuations go, Gilead Sciences' Short term Debt skyrocketed by 29539.67% in 2023, and later crashed by 5516.47% in 2024.
- Over the past 5 years, Gilead Sciences' Short term Debt (Quarter) stood at $1.5 billion in 2021, then surged by 49.93% to $2.3 billion in 2022, then dropped by 20.9% to $1.8 billion in 2023, then rose by 0.95% to $1.8 billion in 2024, then surged by 54.6% to $2.8 billion in 2025.
- Its Short term Debt stands at $2.8 billion for Q3 2025, versus $2.8 billion for Q2 2025 and $2.8 billion for Q1 2025.